Download Symptom Clusters in Patients with Advanced Cancer: Cachexia

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Symptom Clusters in Patients with
Advanced Cancer:
Cachexia, Anorexia & Asthenia

Davis Wilkins, M.D. M.A.-Bioethics
 Fellow, Palliative Medicine
 May 2008
Goals
 Discuss
impact of symptom clusters on
QOL
 Review pathophysiology & current thinking
 Current treatment strategies
 Ongoing research & future directions
Definitions
 Cachexia:
involuntary profound loss of
lean body mass and adipose tissue.
 Anorexia: Loss of appetite
 Asthenia/Fatigue: listlessness, decreased
energy, decreased motivation; physical +
cognitive components
Impact of Anorexia & Cachexia
 Occurs
in up to 20% at dx; up to 80% in
advanced cancer
 Attributed as main cause of death in ~20%
patients
 Loss of >10% of premorbid weight = poor
prognostic indicator & associated w/
decreased survival
Strasser & Bruera, Hematol Oncol Clin N Am 2002
Anorexia & Cachexia, continued
 More

common in solid tumors
Exception: breast CA where fatigue more
common
 Does
not correlate well w/ tumor size or
biology
 Specific complications of tumor location &
treatments may additionally exacerbate

i.e. bowel obstruction & inflammation
Strasser & Bruera, Hematol Oncol Clin N Am 2002
Impact of Asthenia/Fatigue
 Asthenia/Fatigue
has been ranked as the
longest-lasting, most disruptive sx with the
greatest impact on QOL



95% cancer patients endorse this as chief
symptom: most common symptom
Often lasts months or years after treatments
Assessment difficult; multiple contributing
factors
• Cancer, treatment, complications of tx or ca, meds,
other physical & psychological conditions
Barnes & Bruera, Intl J Gynecol Cancer 2002
Additional impact of this sx cluster






Profound sense of loss associated with drastic
changes in body image & ability to be active
Often a cause in people’s withdrawal from social
life
Leads to increases stress around food/feeding
by patient, family, friends
Loss of functional status
Decreased performance status = decreased
treatment candidate
All 3 symptoms also very common in other lifelimiting illnesses: AIDS, COPD, CHF, CKD, RA
Importance of better recognition & treatment
 More
‘silent’ symptoms than pain or
dyspnea; often go unrecognized,
unaddressed
 No good current single therapies
 Probably a common pathway for many
diseases
 Targeted therapies may do much to
improve QOL, possibly even survival.
Concept of symptom clusters

Definition: 3 or more symptoms that occur together, are
stable, and relatively independent of other clusters

Anorexia, cachexia, fatigue: flu-like symptoms that
manifest in cancer patients

Can also be accompanied by:





Somatic complaints/aches
Depression
Chronic nausea
Early satiety
Cognitve impairment
Fan et al. Curr Oncol 2007; Gift, A. Seminar in Onc Nurs 2007
Current common treatments

Most single therapies often not very efficacious

Megesterol
Marinol
Mirtazepine
Olanzapine
SSRI’s

Exceptions:




• Corticosteroids, NSAIDs, ? methylphenidate
Del Fabbro. JAMA 2007.
It really IS all about cytokines….
Pathophysiology of cancer
cachexia & anorexia

Complex metabolic syndrome/aberrant inflammatory response

Pro-inflammatory/catabolic state; peripheral proteins & lipids
mobilized to keep up; decreased sensitivity to orexigenic
compounds

Tumor by-products formed from proteolysis inducing factor (PIF),
lipid mobilizing factor (LMF) & activation of ubiquitin-proteosome
degradative pathway

Host cytokines: IL-1, IL-6, TNF-a, interferon

Host synthesis of acute phase proteins in liver at the expense of
muscle protein, proteolysis, lipolysis, insulin resistance,
decreased lipogenesis, elevated triglycerides, decreased
HDlipoproteins

Neuroendocrine dysregulation & production of anorexigenic
compounds
Del Fabbro et al J Pall Med 2006
Cancer cachexia signaling pathways
Clinical Cancer Research 13, 1356-1361, March 2007
? Role of cytokine genetic
polymorphisms
 Cytokine
production & polymorphisms
recently implicated in severity of cancer
related pain

Ongoing research into patient cytokine gene
polymorphisms as explanation for pain
variability in lung CA patients
• Genes for TNF-alpha, IL-6, and IL-8
Reyes-Gibby et al. Cancer Epidemiol Biomarkers Prev. Dec 2007
Pathophysiology: cachexia &
fatigue
 CA
patients have abnormal muscle, even
when lean body mass = constant & caloric
intake still normal:



Excessive lactate in tumor free muscles
Animal studies show alterations in enzyme
activity and isoenzyme distribution, as well as
in synthesis & breakdown of myofibrils &
sarcoplasmic proteins
Patients w/ early impaired maximal strength
Boddaert, M. et al Curr Opin Oncol 2006
Pathophysiology, continued
 Nutritional
supplements and appetite
stimulation alone cannot overcome
progressive loss of muscle mass.
 Treatments (chemo, XRT, surgery) often
exacerbate tissue damage as well as lead
to deconditioning.
Boddaert, M. et al Curr OpinOncol 2006
Current Pharmacologic
Management: cachexia, anorexia

Goal: delay cachexia, alleviate symptom burden
w/o changing body composition


Progestational agents
• Megesterol
• Corticosteroids
Cannabinoids
• Marinol, dronabinol


Hormonal/anti-catabolic
• Testosterone,oxandrolone, GH
Psychotropics
• Antidepressants, anti-psychotics
Strasser & Bruera Hematol Oncol Clin N Am 2002
Current Pharmacologic
Management: Asthenia
 Corticosteroids
 Progestins

& androgens
Megesterol, testosterone
 Psychostimulants

Methylphenidate, modafenil, perroline
 Cholinesterase

donepezil
inhibitors
Current Research

Immune Modulator therapies




Thalidomide
Melatonin
Progestins- in combination with other drugs
Macronutrients
• (L-carnitine, Omega 3 fatty acids, fish oil)
 B-Agonists,
Antagonists
• Norepinephrine, clenbuterol

Anti-inflammatories

Corticosteroids, NSAIDS, EPA, macrolides
Synergy?
 May
be synergistic if given with other
therapies, due to targeting of multiple
pathways simultaneously

Orexigens
Corticosteroids, progestins

Anti-catabolics
Oxandrolone, testosterone, GH

Anti-inflammatories
NSAIDs, EPA, melatonin, macrolides
Yennu, Del Fabbro & Bruera, AAHPM, 2008
Corticosteroids
Mechanism unknown. ? Related to central
euphoria in combination with influence on
prostaglandin metabolism & cytokine release.
Improve appetite, food intake, sense of well-being,
performance status in advanced CA pts up to 4
weeks. NO significant weight gain.


Pred 10-40 mg/day; dex 1-8 mg bid
Longer use may induce myopathy, infxn,GIB, leading
to worsening asthenia
Lundstrom (sweden)2005, Bruera 1995
Melatonin

Most potent endogenous anti-oxidant



Direct ROS scavenger & stimulates other anti-ox’s
Has anti-tumor effects via multiple targets & may improve
survival?
Recent studies:



In many CA, melatonin production decreased
Adding melatonin enhances PPI protective effects & perhaps
decreases chemo side effects
Improves multiple sx in solid tumor pts as well as decreases TNFa serum levels, pain levels from 7-10/102-4/10.
• 20 mg/day x 4 weeks vs placebo, then crossover, then all (RCT)
• (synthetic not cow) (IR not SR)

Downside: hard to assure quality of product/not FDA
regulated. Need more trials/data.
Plissoni (Italy) 2007; Del Fabbro AAHPM 2008
Thalidomide

In-vitro:




Modulate cytokines w/ CNS effects
Recent studies:



Inhibits TNF-a, IL-6, IL-12 @ transcriptional level.
Switches TH1->TH2 type cytokines; inhibits NFkB
100-300 mg/day significantly improves mult. Sxs
Superior to Megace for improving appetite, modest decrease in
wt. loss; side effect: + improved sleep
Downside:



Narrow therapeutic window,
Combo w/ decadron = early data suggest highly thrombogenic
Unavailable in US except in CA Rx, research setting
• Dirt cheap in rest of world, ($200/tablet here)
Bruera, AAHPM, 2008
Modafenil (Provigil)




Novel wake-promoting agent
 Increases release of monoamines, elevates histamine
in certain brain regions.
 Unlikely to have addiction potential
 May have neuroprotective effects
Well tolerated; less side effects than than
psychostimulants
Dosing: start at 50 mg qam; titrate to 100-200 mg/day.
(400 mg/d for narcolepsy)
Downside: HA, nausea, insomnia, anxiety ;
new/experimental. $$

Assessment & Management of
Cancer Related Anorexia,
Cachexia
Strasser & Bruera, Hematol Oncol Clin N Am 2002
Assessment & Management of
Cancer Related Asthenia/Fatigue
Algorithm for
assessment and
management of
cancer-related fatigue
From the NCCN 2002 cancer-related
fatigue guideline, Supportive Care
Practice Guidelines in Oncology
Non-pharmacologic measures

Nutritional support, counseling


Meta-analysis of TPN in cancer patients showed
decreased survival, increased susceptibility to
infection; some patients may maintain weight w/ oral
supplements for short time.
Palliate other major contributing symptoms &
reversible causes:

Chronic nausea, dyspnea, deconditioning,
depression, mucositis, GI obstruction, anemia,
dehydration, pain, metabolic derangements
Nonpharmacologic measures,
continued

Increase activity as able
• Benefit of resistance and endurance training on improved
mood, quality of sleep, muscle mass maintenance


Stress management, supportive counseling
Reframe family/pt. understanding
• Not: ‘starving to death’ but complex metabolic abnormalities
caused by the cancer
• Giving additional food will not result in additional fat or
muscle restoration
• Best chance may be to try and treat with multiple meds, but
need to weigh risk-benefit, pt. ability/desire to take pills
Current novel research








Targeted therapies

Proteasome inhibitors

TNF inhibitors

Monoclonal antibodies to IL-6
Anabolic cytokines (IL-15)
Specific cannabinoid-receptor antagonists
Role of Grehlin (‘gut-brain’ hormone) , leptin
Alpha-melanocyte-stimulating hormone
Growth Hormone/IGF/IGF-I treatments
Immunonutrition

(omega 3 EFA, L-arginine, L-carnitine glutamine, nucleotides)
Anti-cytokine approaches

Anti-sense NFkappa-B

Soluble TNF-alpha receptors

Cytokine antagonists (pentoxifylline, bradykinin antagonists)
Strasser & Bruera Hematol Oncol Clin N Am 2002
Further research needed
 Need




trials with patient-centered endpoints
?Does weight gain/increased lean body mass
lead to better survival?
Function?
QOL?
Improved chemo/XRT tolerance?
Bibliography
Barnes, EA & Bruera, E. “Fatigue in patients with advanced cancer: A review.” Intl Jour
Gynecol Cancer Sept 2002; 12(5), 424-28.
Boddaert et al.” On our way to targeted therapy for cachexia in cancer?” Curr Opin
Oncolo 2006 18:335-340.
Del Fabbro. “Cachexia & Wasting: A Modern Approach.” JAMA Feb 7,2007 297(5)536—
7.
Del Fabbro et al. “ Symptom Control in Palliative Care—Part II: Cachexia, Anorexia, and
Fatigue.” Journal of Palliative Medicine 2006 9 (2); 409-421.
Fan, G, et al. “Symptom Clusters in Cancer Patients: A review of the literature.” Curr
Oncol. October 2007; 14(5)173-179.
Gift, A. Symptom Clusters Related to Specific Cancers.” Seminars in Onc Nursing, May
2007, 23(2): 136-141
Morrow et al. Management of Cancer-Related Fatigue. Cancer Investigation, 2005,
23:229-239
Reyes-Gibby et al. “Cytokine genes and pain severity in lung CA; exploring the
influence..”Cancer Epidemiol Biomarkers Prev 2007 Dec; 16(12)2745-51.
Strasser F, & Bruera, E. “ Update on Anorexia & Cachexia” Hematol Oncol Clin N AM
2002 (16) 589-617.
Swarnali, A, & Guttridge, D. “Cancer Cachexia Signaling Pathways Continue to Emerge
Yet Much Still Points to the Proteasome” Clinical Cancer Research 13, 1356-1361,
March 2007
Yennurajalingam S, and Bruera E. “Palliative management of fatigue at the close of life:
“It feels like my body is all worn out!” JAMA 2007; 297 (3): 295-304